AC Immune Reports Second Quarter 2021 Financial Results and Provides Corporate Update
Announced strategic acquisition of industry-leading Parkinson’s disease vaccine and equity investment led by key investors in Covid-19 vaccine innovator BioNTech SE
ACI-24 full Phase 1b results presented at AAIC 2021 support the continued clinical development of anti-Abeta vaccine approaches in Down syndrome-related Alzheimer’s disease
Expanded Phase 1b/2 anti-pTau Alzheimer’s vaccine trial in collaboration with Janssen Pharmaceuticals, Inc. to support the program’s continued development
Strong financial position of CHF 199.1 million in cash ensures the Company is fully financed through at least Q1 2024
AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, today reported its financial results for the quarter ended June 30, 2021, and provided a corporate update.